Drug updated on 4/16/2024
| Dosage Form | Injection (intravenous: 2 g/vial (1 g meropenem (equivalent to 1.14 g meropenem trihydrate) and 1 g vaborbactam)) |
| Drug Class | Penem antibacterial and beta-lactamase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria.
Summary
- Meropenem and vaborbactam (Vabomere) is indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonectitis caused by designated susceptible bacteria.
- Two systematic reviews/meta-analyses were reviewed to gather information about Vabomere's efficacy in treating cUTIs.
- The first review found that novel antibiotics, such as meropenem/vaborbactam, demonstrated a higher clinical cure rate (CCR) and microbiological eradication rate at test of cure compared to conventional antibiotics used for cUTIs.
- However, there was no significant difference observed in CCR or risk of treatment-emergent adverse events between the intervention group treated with novel antibiotics like Vabomere and control groups at end of treatment according to this study.
- The second meta-analysis revealed that meropenem/vaborbactam had higher clinical and microbiological success rates than other carbapenems when treating cUTI but also showed a higher risk of adverse events.
- This analysis suggested meropenem/vaborbactam as a first-choice treatment especially for complicated urinary tract infections caused by carbapenem-resistant uropathogens due its high effectiveness despite the increased risk associated with it.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Vabomere (meropenem and vaborbactam) Prescribing Information. | 2021 | Melinta Therapeutics, LLC Lincolnshire, IL |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials. | 2023 | International Journal of Antimicrobial Agents |
| Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection. | 2020 | Medicine |